Researchers at the University of Rochester Medicine and the University of Copenhagen have developed a gene therapy delivery platform that uses engineered adeno-associated viruses (AAVs) and the brain’s glymphatic system to bypass the blood-brain barrier. According to a study published in Nature Biotechnology, this method successfully targets human glial progenitor cells, offering a potential pathway for treating neurological conditions such as Huntington’s disease and multiple sclerosis.
Engineering Viral Vectors for Human Glial Targeting
Delivering genetic material to the brain has long been hindered by the blood-brain barrier and the risk of off-target effects in peripheral organs. To solve this, the research team, led by Steve Goldman, MD, PhD, co-director of the Center for Translational Neuromedicine at URochester, created a library of modified AAV5 viral vectors. By altering the vectors’ capsids, the team screened for variants that could effectively infect human glial progenitor cells and their descendants, including astrocytes and oligodendrocytes.
Goldman noted that human cells possess distinct molecular signatures compared to mouse models. By selecting vectors under biologically relevant conditions in mice transplanted with human glial progenitor cells, the researchers identified candidates with a specific preference for human glia. This precision is essential, as glial dysfunction is a known driver in the progression of various neurological disorders.
Harnessing the Glymphatic System for Drug Distribution
Rather than attempting to force therapies across the blood-brain barrier from the bloodstream, the research team utilized the brain’s own fluid transport pathways. They delivered the engineered AAVs into the cisterna magna—a fluid-filled compartment at the base of the brain—and applied hypertonic treatment to enhance fluid uptake into the glymphatic network.
According to Goldman, this strategy allows for broad distribution throughout the brain tissue while minimizing exposure to peripheral organs like the liver.
Future Applications in Neurodegenerative Disease
The immediate clinical focus for this platform includes pediatric lysosomal storage diseases and other inherited white matter disorders where glial cells lack critical enzymes. Because these conditions have well-defined biological targets, they serve as ideal candidates for the initial application of this delivery technology.
Looking further ahead, the team is investigating the potential for treating neurodegenerative conditions, including:
- Multiple Sclerosis: Targeting glial cells to promote recovery or stop disease progression.
- Huntington’s Disease: Replacing diseased cells with healthy glial progenitor cells.
- Age-related white matter loss: Utilizing gene therapy to restore cellular function in aging brains.
Goldman’s lab is currently exploring the use of artificial intelligence to design future viral capsids with even more specific targeting characteristics, potentially allowing for disease-specific and cell-population-specific therapies.
Frequently Asked Questions
How does this method avoid the blood-brain barrier?
The researchers deliver the therapy directly into the cisterna magna, a fluid-filled compartment at the base of the brain, and use the glymphatic system to distribute the vectors, bypassing the need to cross the blood-brain barrier from the blood.
Why are glial cells the focus of this research?
Glial cells are recognized as major drivers in the progression of many neurological disorders. Replacing or correcting these cells is viewed as a vital strategy for treating diseases like Huntington’s.
What are the next steps for this technology?
The team is currently investigating the integration of artificial intelligence to further refine the design of viral capsids, aiming to create highly specific treatments for various neurodegenerative conditions.
